Xuan-Guang Li

Greater survival benefits in small cell lung cancer patients: a real-world study with immune checkpoint inhibitors therapy

Background Small-cell lung cancer (SCLC) is a highly aggressive neuroendocrine malignancy. Immune checkpoint inhibitors (ICIs) combined with chemotherapy have become a standard first-line treatment for extensive-stage SCLC; however, their effectiveness across different clinical settings in real-world practice remains i...